洛伐他汀对原发性肾病综合征患者微炎症状态的影响

Influence of Lovastatin on the Micro-inflammation Status of Primary Nephrotic Syndrome Patients

【目的】观察洛伐他汀对原发性肾病综合征患者炎症反应标记物白细胞介素-6(IL-6)和C反应蛋白(CRP)的影响,探讨他汀类药物对原发性肾病综合征患者微炎症状态的疗效。【方法】原发性肾病综合征患者36例,随机分为洛伐他汀治疗组和非洛伐他汀治疗组,分别观察治疗前、治疗16周后甘油三酯(TG)、总胆固醇(TC)、IL-6和CRP水平。【结果】①原发性肾病综合征患者TG、TC、IL-6、CRP水平均显著高于健康人群(P<0.01);②治疗16周后,洛伐他汀治疗组TC、TG、IL-6、CRP的水平与治疗前相比均明显下降(P<0.01),与非洛伐他汀治疗组相比也显著降低(P<0.05)。【结论】应用洛伐他汀治疗能改善原发性肾病综合征患者的微炎症状态。

[Objective] To observe the influence of lovastatin on the inflammatory reaction marker interleukin-6 （IL-6） and C-reactive protein （CRP） of the primary nephrotic syndrome patients, and to investigate the therapeutic effect of statins on the micro-inflammation status of primary nephrotic syndrome patients. [Results]Thirty six examples of primary nephrotic syndrome patients were randomly divided into two groups, lovastatin therapy group and non-lovastatin therapy group. The level of triglyceride （TG）, total cholesterol （TC）, IL-6 and CRP were evaluated before and after 16-week long treatment. [Results]The levels of TG, TC, IL-6 and CRP of primary nephrotic syndrome patients were significantly higher than those of healthy controis （ P〈0.01）. The levels of TG, TC, IL-6 and CRP of the lovastatin therapy group were obviously decreased after 16-week long treatment and were notably lower than those of non-lovastatin therapy group （ P 0.05）. [Conclusion]Lovastatin is an effective medicine to improve the micro-inflammation status of primary nephrotic syndrome patients.